Cybin (OTCMKTS:CYBN) Shares Down 5.7% – Time to Sell?

Shares of Cybin Inc. (OTCMKTS:CYBN) traded down 5.7% during mid-day trading on Monday . The company traded as low as $6.20 and last traded at $6.34. 269,681 shares changed hands during mid-day trading, an increase of 3% from the average session volume of 261,761 shares. The stock had previously closed at $6.72.

Cybin Stock Performance

The firm has a fifty day moving average of $8.43 and a 200 day moving average of $9.21. The firm has a market capitalization of $134.45 million, a PE ratio of -32.95 and a beta of 0.61.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.